Forest hit by US product delays
This article was originally published in Scrip
Executive Summary
Forest Laboratories has suffered setbacks to its pipeline after a meeting with the US FDA prompted it to postpone its NDA for the COPD treatment aclidinium bromide, which is being developed under a partnership with Almirall. On the same day, the company announced it was pushing back the US launch of its SNRI Savella (milnacipran HCl) for fibromyalgia while it seeks approval for a minor change.